
Opinion|Videos|December 3, 2024
Comparing the Latest Stool- Based and Blood-Based Colorectal Cancer Screening Tests
Author(s)Vivek Kaul, MD
Key Takeaways
- Stool DNA tests, like Cologuard, demonstrate high sensitivity (92%) and specificity (87%) for colorectal cancer detection, analyzing DNA markers and hemoglobin in stool samples.
- Blood-based tests, such as Epi proColon, detect circulating tumor DNA or methylated DNA markers, offering a less invasive alternative to colonoscopy.
Vivek Kaul, MD, discusses the sensitivity and accuracy of the stool DNA test, providing relevant data, while also describing the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests.
Advertisement
- What do we know about the sensitivity and accuracy of the stool DNA test, including any relevant data?
- Can you describe the role of blood-based tests in colorectal cancer screening and how they complement or differ from stool-based tests?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia
2
What New 26-Week COMP006 Data Mean for TRD, With Boadie Dunlop, MD
3
Daily Inhaled TPIP Improved PAH Measures at 12 Months in OLE
4
FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD
5







































































